Industry News
Biotechnology Industry News
Xoma, which styles itself as a…
Xoma, which styles itself as a “biotech royalty aggregator,” has struck a deal to acquire Generation Bio for roughly $4.29 per share at the time of the planned merger’s close.
Sanofi is back with its second…
Sanofi is back with its second pact of the day, this time announcing a licensing deal for a South Korean biotech’s antibody therapy designed to treat Alzheimer's disease.
MapLight Therapeutics is the…
MapLight Therapeutics is the latest biotech to want a turn with Alphabet’s AI spinout SandboxAQ. The neuro-focused company is penning a strategic collaboration meant to develop new therapies for central nervous system diseases.
Aviceda Therapeutics has hit a…
Aviceda Therapeutics has hit a snag in its goal to deliver a new treatment for geographic atrophy, an advanced form of dry age-related macular degeneration. The biotech’s lead asset, AVD-104, failed to beat Astellas’ Izervay
Cell therapy company Link Cell…
Cell therapy company Link Cell Therapies is launching with $60 million and a mission to develop potent CAR-T therapies that go after a range of tumors while avoiding patients' healthy tissue.
Seattle’s Adaptive…
Seattle’s Adaptive Biotechnologies is linking up with Pfizer on two non-exclusive pacts that leverage the biotech’s bespoke T-cell receptor discovery engine and large-scale immune receptor antigen-mapping data. At the same time, Dren Bio said it
AI drug developer Chai Discovery…
AI drug developer Chai Discovery has brewed up a $130 million series B to juice its development of a “computer-aided design suite” for new therapeutics.
Immunome’s investigational oral…
Immunome’s investigational oral therapy slashed the risk of disease progression or death by 84% for patients with desmoid tumors, data one analyst is deeming a “near best-case outcome.”
Kyverna Therapeutics looks all the…
Kyverna Therapeutics looks all the more likely to win the first FDA approval for a CAR-T therapy in an autoimmune disease after a registrational trial showed “highly statistically significant” benefits for the company’s CD19 agent
After spending the year angling…
After spending the year angling for a new approval in multiple sclerosis, Sanofi's stockings may hang empty this holiday season—at least when it comes to tolebrutinib in non-relapsing secondary progressive multiple sclerosis.
Fresh off a $153 million series E…
Fresh off a $153 million series E round, Arthrosi Therapeutics is skipping an IPO route and is instead being bought up for a potential value of $1.5 billion from Swedish biopharma Sobi.
After a year marked by dramatic…
After a year marked by dramatic ups and downs, William Blair analysts say 2026 could carry forward the industry’s current momentum—as long as strong clinical data continue to be rewarded and companies can bring drugs
Zealand Pharma may be gearing up…
Zealand Pharma may be gearing up for a high-stakes year of obesity readouts, but the Danish biopharma thinks the brain could hold the key to the company’s long-term success.
A key late-stage trial of Arcus…
A key late-stage trial of Arcus Biosciences and Gilead’s anti-TIGIT antibody domvanalimab has flopped, leading Arcus to refocus its R&D priorities and abandon several trials of the drug.
Cycle Pharmaceuticals is circling…
Cycle Pharmaceuticals is circling up Applied Therapeutics, acquiring the rare disease biotech after an extremely tumultuous year for the latter that began with an FDA rejection at the end of 2024.
Rezolute’s stock has plunged 87%…
Rezolute’s stock has plunged 87% after the company’s rare disease drug flunked the final clinical test ahead of a planned approval application.
Eli Lilly has surpassed…
Eli Lilly has surpassed analysts’ highest hopes for the efficacy of retatrutide, linking the triple agonist to 28.7% weight loss and a 75.8% reduction in pain scores in patients with obesity and knee osteoarthritis. But
Moderna has tapped Swedish…
Moderna has tapped Swedish long-acting drug formulation company Nanexa to improve the delivery of up to four injectable therapies.
Barreling toward the end of its…
Barreling toward the end of its cash runway, GRI Bio has shared phase 2a data in idiopathic pulmonary fibrosis and made the case for further development of its potentially disease-modifying therapy.
OTR may still be keeping its own…
OTR may still be keeping its own pipeline under wraps, but Zealand has seen enough promise in the Chinese biotech’s platform to agree to hand over up to $30 million in upfront payments.